Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Trastuzumab (HER2-targeted therapy)
Treatment for Breast cancer
Typical Dosage: 4 mg/kg loading dose, then 2 mg/kg weekly or 8 mg/kg loading, then 6 mg/kg every 3 weeks
Effectiveness
85%
Safety Score
55%
Clinical Trials
89
Participants
75K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
4 mg/kg loading dose, then 2 mg/kg weekly or 8 mg/kg loading, then 6 mg/kg every 3 weeks
Time to Effect
Weeks to months
Treatment Duration
Typically 1 year (adjuvant)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$4,000
Side Effect Mgmt:$2,000
Total Annual:$56,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$85,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$93,333
Cost per Remission
$186,667
Comparison vs Chemotherapy alone
Cost Difference
+$30,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Trastuzumab (HER2-targeted therapy) Outcomes
for Breast cancer
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+60%
Remission Rate
+30%
Common Side Effects
Cardiotoxicity (decreased LVEF)
+5%
Infusion-related reactions
+20%
Diarrhea
+25%
Nausea
+20%
Fatigue
+30%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
13 active trials recruiting for Trastuzumab (HER2-targeted therapy) in Breast cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
NCT04928261ACTIVE NOT RECRUITINGPHASE4
52 participants
INTERVENTIONAL
Ottawa, Canada
Started: Dec 13, 2021
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
NCT06843681ENROLLING BY INVITATIONPHASE2
54 participants
INTERVENTIONAL
Guangzhou, China
Started: Mar 1, 2025
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
NCT07528898NOT YET RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Shijiazhuang, China
Started: May 1, 2026
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
NCT07589699NOT YET RECRUITINGPHASE4
59 participants
INTERVENTIONAL
Started: May 31, 2026
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT06450314RECRUITINGPHASE2
170 participants
INTERVENTIONAL
Rennes, France
Started: Jan 25, 2025
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
NCT04983121RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Shenyang, China
Started: Aug 1, 2021
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
NCT04680442RECRUITINGPHASE2
130 participants
INTERVENTIONAL
Porto Alegre, Brazil +7 more
Started: Jul 1, 2021
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
NCT07459673RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Mar 4, 2026
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
NCT07294534NOT YET RECRUITINGPHASE2, PHASE3
817 participants
INTERVENTIONAL
Started: Jan 27, 2026
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294508RECRUITINGPHASE2, PHASE3
706 participants
INTERVENTIONAL
Beijing, China
Started: Feb 27, 2026
Detect V / CHEVENDO (Chemo vs. Endo)
NCT02344472ACTIVE NOT RECRUITINGPHASE3
271 participants
INTERVENTIONAL
Ulm, Germany
Started: Sep 1, 2015
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
NCT07340398RECRUITINGPHASE2
200 participants
INTERVENTIONAL
Hangzhou, China
Started: Dec 25, 2025
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782NOT YET RECRUITINGPHASE2
202 participants
INTERVENTIONAL
Started: Nov 1, 2025
Completed Clinical Trials
4 completed trials for Trastuzumab (HER2-targeted therapy) in Breast cancer
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
NCT07416409COMPLETED
80 participants
OBSERVATIONAL
Cairo, Egypt
Started: Jun 10, 2023
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
NCT02286843COMPLETEDNA
49 participants
INTERVENTIONAL
New York, United States
Started: Nov 6, 2014
Cardiac Safety Study in Patients With HER2 + Breast Cancer
NCT01904903COMPLETEDPHASE2
31 participants
INTERVENTIONAL
Washington D.C., United States +1 more
Started: Oct 1, 2013
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
NCT01922921COMPLETEDPHASE1, PHASE2
31 participants
INTERVENTIONAL
Seattle, United States
Started: Feb 5, 2014
Showing 20 of 105 total trials